Starget Pharma
Starget Pharma develops a novel somatostatin-based targeted therapy platform.
About
Starget Pharma, founded in 2019 and headquartered in Ramat Hasharon, Israel, operates as a clinical biotechnology company dedicated to advancing oncology treatments. The company is focused on pioneering a new class of AI-powered Smart Targeted Radioligands. These innovative therapies are specifically engineered for precision oncology, with the aim of effectively addressing hard-to-heal cancers.
The company's research and development efforts are centered on creating a new generation of targeted radiopharmaceutical technologies. This includes the development of a novel somatostatin-based targeted therapy platform, which is designed to deliver precise therapeutic agents to solid tumors. Starget Pharma's work contributes to the biotechnology research industry by developing specialized solutions for complex cancer cases.
Financial History
Starget Pharma has raised $16.4M across 1 funding round.
Frequently Asked Questions
What specific technological approach does Starget Pharma employ for its cancer therapies?
Starget Pharma utilizes a new class of AI-powered Smart Targeted Radioligands and a novel somatostatin-based targeted therapy platform. These technologies are engineered to deliver therapeutic agents precisely to solid tumors.
Which types of cancer are the primary focus for Starget Pharma's treatments?
Starget Pharma primarily focuses on developing precision oncology treatments for hard-to-heal cancers and solid tumors. Their therapies are designed to address challenging cancer diagnoses effectively.